ImmunoChem Therapeutics, a Northwestern University spin-out, is developing two clinical assets targeting abnormal brain inflammation, a major contributor to cognitive decline in Alzheimer’s disease, other dementias, brain injury, stroke and epilepsy. Development to date has been supported by non-dilutive, peer-reviewed NIH SBIR and STTR grants. An extensive portfolio of USA and international patents cover composition of matter and methods of use. The founding team and scientific advisors are experienced in pre-clinical and clinical development. ICT is raising private funds to complete Phase 2a clinical studies, and is seeking potential later stage partners. Because our drug development platform targets disease progression pathways common across several diseases, later clinical development can be staged for additional major or neglected CNS indications. Another opportunity we are looking into is a cytokine storm due to coronavirus infection.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):